Journal of Shanghai University >
Human embryonic stem cell-derived cardiomyocytes model establishment and systemic identification scheme
Received date: 2017-04-03
Online published: 2017-06-30
Cardiomyocytes is useful in the study of many cardiovascular diseases, while human cardiomyocytes are difficult to obtain and culture. With multi-directional differentiation properties, human embryonic stem cells can provide cell resources in vitro. This study aims to establish a useful protocol to induce the differentiation of human embryonic stem cells into cardiomyocytes, and observe identification of human cardiomyocytes. Expression of stem cell markers including Cripto, Dnmt3b, Wnt3, KIF4, Oct4, SOX2 and Nanog decrease during differentiation while cardiac progenitor cell marker Nkx2.5 and cardiomyocytes specific markers TnnT2 and a-actinin increase. Ratios of TnnT2 positive cells, α-actinin positive cells, TnnT2 and α-actinin double positive cells are 90.80%, 91.00%, and 90.91%. These results indicate that human embryonic stem cells can be efficiently induced into cardiomyocytes in the proposed protocol. In conclusion, differentiation of human embryonic stem cells into cardiomyocytes has been successfully induced and an identification scheme has been established, and markers have been detected through quantitative PCR and immunofluorescence stainings. The protocol will facilitate better understanding
of pathogenesis of cardiovascular diseases and enable better cardiotoxicity drug screening.
Key words： cardiomyocytes; cell differentiation; human embryonic stem cell
CHEN Xinxin, LIU Zhuyuan, GU Huanyu, ZHOU Lei . Human embryonic stem cell-derived cardiomyocytes model establishment and systemic identification scheme[J]. Journal of Shanghai University, 2017 , 23(3) : 378 -386 . DOI: 10.12066/j.issn.1007-2861.1939
[1] Sartiani L, Bettiol E, Stillitano F, et al. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach [J].
Stem Cells, 2007, 25(5): 1136-1144.
[2] Mummery C, Van Der Heyden M A, De Boer T P, et al. Cardiomyocytes from human and mouse embryonic stem cells [J]. Methods in Molecular Medicine, 2007, 140: 249-272.
[3] Mummery C. Cardiomyocytes from human embryonic stem cells: more than heart repair alone [J]. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology,
2007, 29(6): 572-579.
[4] Wendel J S, Ye L, Tao R, et al. Functional effects of a tissue-engineered cardiac patch from human induced pluripotent stem cell-derived cardiomyocytes in a rat infarct
model [J]. Stem Cells Translational Medicine, 2015, 4(11): 1324-1332.
[5] Pekkanen-Mattila M, Chapman H, Kerkela E, et al. Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype[J]. Experimental Biology and Medicine, 2010, 235(4): 522-530.
[6] Zhang J, Wilson G F, Soerens A G, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells [J]. Circulation Research, 2009, 104(4): e30-e41.
[7] Chan H Y, Cheung M C, Gao Y, et al. Expression and reconstitution of the bioluminescent Ca(2+) reporter aequorin in human embryonic stem cells, and exploration of the presence
of functional IP3 and ryanodine receptors during the early stages of their differentiation into cardiomyocytes [J]. Science China Life Sciences, 2016, 59(8): 811-824.
[8] Binah O, Dolnikov K, Sadan O, et al. Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes [J]. Journal of Electrocardiology, 2007, 40: S192-
S196.
[9] Steel D, Hyllner J, Sartipy P. Cardiomyocytes derived from human embryonic stem cellscharacteristics and utility for drug discovery [J]. Current Opinion in Drug Discovery & Development, 2009, 12(1): 133-140.
[10] Rathjen P D, Lake J, Whyatt L M, et al. Properties and uses of embryonic stem cells: prospects for application to human biology and gene therapy [J]. Reproduction, Fertility, and Development, 1998, 10(1): 31-47.
[11] Adler S, Lindqvist J, Uddenberg K, et al. Testing potential developmental toxicants with a cytotoxicity assay based on human embryonic stem cells [J]. Alternatives to Laboratory Animals, 2008, 36(2): 129-140.
[12] Rovida C, Vivier M, Garthoff B, et al. ESNATS conference—the use of human embryonic stem cells for novel toxicity testing approaches [J]. Alternatives to Laboratory Animals, 2014,
42(2): 97-113.
[13] Genschow E, Spielmann H, Scholz G, et al. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods [J]. Alternatives to Laboratory Animals, 2002, 30(2): 151-176.
[14] Muller M, Fleischmann B K, Selbert S, et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro [J]. Faseb Journal, 2000, 14(15): 2540-2548.
[15] Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications [J]. Stem Cell Reviews, 2010, 6(1): 108-120.
[16] Xu C, Police S, Hassanipour M, et al. Efficient generation and cryopreservation of cardiomyocytes derived from human embryonic stem cells [J]. Regenerative Medicine, 2011,
6(1): 53-66.
[17] Arbel G, Caspi O, Huber I, et al. Methods for human embryonic stem cells derived cardiomyocytes cultivation, genetic manipulation, and transplantation [J]. Methods in Molecular
Biology, 2010, 660: 85-95.
/
| 〈 |
|
〉 |
